Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Debio 4126 controlled release - Debiopharm

Next Previous
X
Search
Drug Profile

Debio 4126 controlled release - Debiopharm

Alternative Names: Debio-4126

Latest Information Update: 14 Jul 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Unknown
  • Developer Debiopharm
  • Class Antineoplastics; Somatostatins
  • Mechanism of Action Growth hormone-releasing hormone inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Acromegaly; Neuroendocrine tumours
  • Preclinical Cancer

Most Recent Events

  • 18 May 2022 Phase-I clinical trials in Acromegaly (Combination therapy) in Sweden, Spain, Russia, Portugal, Poland, Italy, Hungary, Israel, Germany, United Kingdom, France, Denmark (IM) (NCT05364944)
  • 18 May 2022 Phase-I clinical trials in Neuroendocrine tumours (Combination therapy) in Sweden, Spain, Russia, Portugal, Poland, Italy, Israel, Hungary, Germany, France, United Kingdom, Denmark (IM) (NCT05364944)
  • 06 May 2022 Debiopharm plans a phase I OXTEND-01 trial for Acromegaly and Neuroendocrine tumours (Combination therapy) (IM) in May 2022 (NCT05364944)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top